Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar to discuss the company's commercial preparations for treatment-resistant depression (TRD) and clinical trial plans for post-traumatic stress disorder (PTSD) from 10:00-11:30 am ET on January 7, 2026. The discussion will include KOL and industry leaders' perspect.

Business Wire • Dec 9, 2025

Compass Pathways to Participate in Two Investor Conferences in December

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the following December investor conferences: 8th Annual Evercore Healthcare Conference – Coral Gables, FL: Fireside chat at 10:00am ET on December 2, 2025 Piper Sandler 37th Annual Healthcare Conference – New York, NY: Fireside chat at 1:30pm ET on December 3, 2.

Business Wire • Nov 20, 2025

Compass Pathways to Participate in Stifel 2025 Healthcare Conference

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be ac.

Business Wire • Nov 5, 2025

Compass Pathways to expedite launch timing of its experimental depression therapy

Drug developer Compass Pathways said on Tuesday it is pulling forward the expected launch timing of its experimental psilocybin-based depression therapy by 9 to 12 months.

Reuters • Nov 4, 2025

COMPASS Pathways plc (CMPS) Q3 2025 Earnings Call Transcript

COMPASS Pathways plc ( CMPS ) Q3 2025 Earnings Call November 4, 2025 8:00 AM EST Company Participants Stephen Schultz - Senior Vice President of Investor Relations Kabir Nath - CEO & Director Teri Loxam - CFO, Principal Financial Officer & Principal Accounting Officer Lori Englebert - Chief Commercial Officer Steve Levine - Chief Patient Officer Conference Call Participants Joshua Schimmer - Cantor Fitzgerald & Co., Research Division Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Judah Frommer - Morgan Stanley, Research Division Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Chi Wen Chin - TD Cowen, Research Division Patrick Trucchio - H.C. Wainwright & Co, LLC, Research Division Sumant Kulkarni - Canaccord Genuity Corp., Research Division Presentation Operator Good morning, ladies and gentlemen, and thank you for standing by.

Seeking Alpha • Nov 4, 2025

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 mon.

Business Wire • Nov 4, 2025

NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression

Collaboration will leverage AI-powered neural analysis and Compass' expertise in psychedelic drug development to advance new therapies for mental health KEARNY, N.J. , Oct. 30, 2025 /PRNewswire/ -- NeuroKaire, a pioneer in precision psychiatry and neurology, has launched an R&D collaboration with Compass Pathways, a leading biotechnology company dedicated to transforming mental health care.

PRNewsWire • Oct 30, 2025

Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the appointment of Dr. Jeffrey Jonas to its Board of Directors, effective immediately. Dr. Jonas brings more than three decades of leadership in pharmaceutical research and development, with a particular focus on neuroscience. As part of this Board transition, Thomas Lönngren will retire from his.

Business Wire • Oct 29, 2025

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the third quarter ended September 30, 2025, and provide an update on recent developments, on November 4, 2025. Compass management will host a conference call at 8:00 am ET (1:00 pm UK) on November 4, 2025. A live webcast of the call will be available on t.

Business Wire • Oct 28, 2025

COMPASS Pathways Plc (CMPS) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

COMPASS Pathways plc (NASDAQ:CMPS ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:45 AM EDT Company Participants Kabir Nath - CEO & Director Guy Goodwin - Chief Medical Officer Lori Englebert - Chief Commercial Officer Teri Loxam - CFO, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Presentation Judah Frommer Equity Analyst All right. Good morning, everyone.

Seeking Alpha • Sep 9, 2025